Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema

Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.

Wegovy(R) (semaglutide injection) Receives Conditional Marketing Authorization from Health Canada as the First and Only Treatment for Adults with Non-Cirrhotic MASH, a Serious ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Are Ozempic and Wegovy knock-offs safe? What to know about compounded GLP-1s

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
Zacks.com on MSN

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...
Scripps News on MSN

Eli Lilly seeks FDA approval for pill that maintains weight loss after Wegovy, Zepbound

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping Wegovy or Zepbound injections.